debra brown, pharmd, fascp pharmaceutical consultant ii ... · antipsychotic reduction in nursing...
TRANSCRIPT
![Page 1: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/1.jpg)
Debra Brown, PharmD, FASCP
Pharmaceutical Consultant II Specialist
HMS Training Webinar January 27, 2017
1
![Page 2: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/2.jpg)
Describe nationwide prevalence and types of elderly dementia + define BPSD
Define “psychotropic medications;” delineate potential antipsychotic adverse effects
Identify current CMS regulatory guidance/survey tools to evaluate antipsychotic medication use
Summarize the current national focus on antipsychotic reduction in nursing homes
2
![Page 3: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/3.jpg)
14% of people age 71 and older in the US have dementia
60 – 80% of dementia cases are Alzheimer’s
10% of cases are vascular dementia ◦ However, 50% of elderly with dementia have
evidence of infarcts
Other dementia types: Lewy Body, Parkinson’s, Frontotemporal Lobar Degeneration, Creutzfeld-Jakob, Normal Pressure Hydrocephalus
Source: Alzheimer’s Disease 2016 Facts and Figures, Alzheimer’s Association
3
![Page 4: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/4.jpg)
“Behavioral or Psychological Symptoms of Dementia”
Fluctuate over the course of dementia illness
Reflects consensus by the International Psychogeriatric Association with regard to description of dementia symptom clusters, specifically: ◦ Behavioral: verbal/physical aggression,
disinhibition
◦ Psychological: hallucinations, delusions, paranoia, anxiety, depressed mood, sleep disturbance
4
![Page 5: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/5.jpg)
5
![Page 6: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/6.jpg)
6
Each resident’s drug regimen must be free from unnecessary drugs. An unnecessary drug is any drug when used --
(1) In excessive dose (including duplicate drug therapy); or
(2) For excessive duration; or (3) Without adequate monitoring; or (4) Without adequate indications for its use; or (5) In the presence of adverse consequences which
indicate the dose should be reduced or discontinued; or
(6) Any combinations of the reasons stated in paragraphs (d)(1) through (5) of this section.
![Page 7: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/7.jpg)
Based on comprehensive resident review, the facility must ensure that -- ◦ (1) Residents are not given psychotropic drugs unless
necessary to treat a specific documented condition;
◦ (2) Residents who use psychotropic drugs receive GDRs and behavioral interventions (unless clinically contraindicated) in an effort to discontinue these drugs;
◦ (3) Residents do not receive PRN psychotropic drugs unless necessary to treat a specific documented condition; and
◦ (4) PRN psychotropic drugs are limited to 14 days – if beyond 14 days prescriber documents rationale.
◦ (5) PRN antipsychotic orders are limited to 14 days and cannot be renewed unless the prescriber evaluates the resident for appropriateness of the medication.
7
![Page 8: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/8.jpg)
Definition (CMS Final Rule dated 10/4/16):
“Any drug that affects brain activities associated with mental processes and behavior”
8
![Page 9: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/9.jpg)
Antipsychotics
Antidepressants
Anxiolytics
Sedative-hypnotics
CMS has the authority to add other drugs to the definition through sub-regulatory guidance.
9
![Page 10: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/10.jpg)
Rule out potentially reversible causes of impaired cognition ◦ Delirium, dehydration, electrolyte imbalances,
hypothyroidism, pain, constipation, etc.
◦ Review of current medications/minimize those that can impair cognition
Trial of non-pharmacologic behavior interventions
10
![Page 11: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/11.jpg)
chlorpromazine (generic only)
fluphenazine (generic only)
Haldol (haloperidol)
Loxitane (loxapine)
Moban (molindone)
Navane (thiothixene)
perphenazine (generic only)
thioridazine (generic only)
trifluoperazine (generic only)
11
![Page 12: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/12.jpg)
Abilify (aripiprazole)
Clozaril (clozapine)
Fanapt (iloperidone)
Geodon (ziprasidone)
Invega (paliperidone)
Risperdal (risperidone)
Seroquel (quetiapine)
Zyprexa (olanzapine)
Nuplazid (pimavanserin)
Combination antidepressant and atypical antipsychotic medication:
Symbyax (Prozac & Zyprexa) fluoxetine & olanzapine
12
![Page 13: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/13.jpg)
13
Identified, documented clinical rationale for administering a medication… ◦ Based on assessment of the resident’s condition +
therapeutic goals ◦ Consistent with
Manufacturer’s recommendations and/or clinical practice guidelines
Clinical standards of practice
Medication references
Clinical studies or evidence-based review articles that are published in medical and/or pharmacy journals
Source: Appendix PP, F329
![Page 14: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/14.jpg)
14
Were other potential causes for the symptoms ruled out?
Were physical and/or psychosocial signs, symptoms persistent or significant enough to warrant therapy?
Were non-pharmacological interventions tried? Was the medication clinically indicated to
manage the symptom or condition? and Does the intended or actual benefit justify the
potential risk(s) or adverse consequences associated with the medication, dose, and duration?
14
![Page 15: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/15.jpg)
Within the first year a resident is admitted on an antipsychotic or after facility has initiated: ◦ Facility must attempt GDR in two separate
quarters (with at least one month between attempts) unless clinically contraindicated.
After the first year: ◦ GDR must be attempted annually, unless clinically
contraindicated.
15
![Page 16: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/16.jpg)
For behavioral symptoms related to dementia: ◦ Resident’s target symptoms returned/worsened
after the most recent GDR attempt within the facility; and
◦ The physician has documented the clinical rationale for why any additional attempt at reduction would likely impair the resident’s function or increase distressed behavior.
16
![Page 17: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/17.jpg)
For psychiatric disorder other than dementia: ◦ Continued use is in accordance with relevant current
standards of practice and the physician has documented why attempted reduction would be likely to impair function or cause psychiatric instability by exacerbating an underlying psychiatric disorder; or
◦ Resident’s target symptoms returned/worsened after the most recent GDR attempt within the facility and the physician has documented the clinical rationale for why any additional reduction attempts would be likely to impair the resident’s function or cause psychiatric instability by exacerbating an underlying medical or psychiatric disorder.
17
![Page 18: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/18.jpg)
Elderly are at increased risk for adverse effects and mortality. ◦ Sedation, postural hypotension and falls.
Dementia patients should be assessed for type, frequency, severity, pattern and timing of symptoms.
Dementia patients should be assessed for pain and other potentially modifiable contributors to symptoms.
Comprehensive treatment plan: person-centered non-pharmacological and pharmacological interventions.
Nonemergency use of AP only when symptoms severe, dangerous and/or cause significant distress to the patient + assess risk/benefit.
If risk/benefit favors use of AP, initiate low dose + titrate to minimum effective dose. If no response after 4-week trial, taper and DC.
Source: The American Psychiatric Association Practice Guideline on the Use of
Antipsychotics to Treat Agitation or Psychosis in Dementia, Am J Psychiatry 173:5, May 2016
18
![Page 19: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/19.jpg)
Form CMS-20082 (7/2015) ◦ Has facility met unnecessary medication
requirements for each resident?
◦ System for monitoring/addressing AE + GDR considerations?
◦ Investigation focus (O/I/RR)
◦ Critical Elements for citing assessment, care planning, unnecessary meds and MRR
◦ Refers to Checklist “Care for a Resident with Dementia”
19
![Page 20: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/20.jpg)
For use with Interpretive Guidance at F309
Key considerations for compliance related to: ◦ Assessment and underlying cause identification
◦ Care planning
◦ Implementation of the care plan
◦ Care plan revision/monitoring and follow up
◦ Quality assessment and assurance
20
![Page 21: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/21.jpg)
Utilized during Task 5C resident review ◦ In conjunction with Assessment of Drug
Therapies
Links unnecessary medications with the medication regimen review
Identifies s/sx that may be medication-related adverse effects (AEs) ◦ How did facility assess need + care plan resident
medications?
Did pharmacist identify actual/potential medication AEs as irregularity during MRR?
21
![Page 22: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/22.jpg)
Survey probes ◦ Medical symptoms leading to chemical restraint?
◦ Used to restrict function or freedom of movement?
◦ Has facility attempted less restrictive alternative?
◦ Did resident/representative make an informed choice regarding the medication (risk/benefit/alternatives)?
◦ Does facility use the Care Area Assessments to evaluate the appropriateness of the medication?
◦ Has facility re-evaluated the need for a chemical restraint?
22
![Page 23: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/23.jpg)
CMS S & C Letter 16-15-NH
Issued March 25, 2016
Provided list of F tags with revised guidance to emphasize risk of psychosocial harm
Included F329 Draft Revision, highlighting guidance related to how unnecessary medication use can cause psychosocial harm
Included language revision in the Psychosocial Outcome Severity Guide (Appendix P)
23
![Page 24: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/24.jpg)
May 2012: CMS National Initiative to Improve Dementia Care ◦ Goal: reduce NH antipsychotic use by 15% end of
2012
◦ Focus on non-pharmacologic behavior interventions
◦ “Nursing Home Compare” website posted MDS 3.0 QM antipsychotic use data beginning July 2012
Baseline Q4 2011: 23.9% antipsychotic use (L)
End of Q2 2016: 16.3% antipsychotic use (L)
Relative reduction 31.8% for the time period
24
![Page 25: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/25.jpg)
CA Partnership to Improve Dementia Care and Reduce Unnecessary Antipsychotic Use
Kick-off stakeholder summit 8/17/12 CMS Region IX (CDPH co-sponsor) ◦ Achievements:
Baseline (Q4 2011) 21.6% antipsychotic use (L)
End of Q2 2016: 12.75% antipsychotic use (L)
Relative reduction 40.9% for the time period
CA ranks 8th in the nation (Source: September 2016 CMS data)
25
![Page 26: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/26.jpg)
Multiple training programs/materials available for providers, clinicians, consumers and surveyors on the CMS National Nursing Home Quality Improvement Campaign website: https://www.nhqualitycampaign.org/dementiaCare.aspx
26
![Page 27: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/27.jpg)
Manufacturer’s usage recommendations ◦ FDA
◦ NIH/DailyMed: https://dailymed.nlm.nih.gov/dailymed/index.cfm
Relevant clinical guidelines (partial list) ◦ American Psychiatric Association
◦ Agency for Healthcare Research and Quality (AHRQ)
◦ American Association for Geriatric Psychiatry
27
![Page 28: Debra Brown, PharmD, FASCP Pharmaceutical Consultant II ... · antipsychotic reduction in nursing homes 2 ... fluphenazine (generic only) ... Key considerations for compliance related](https://reader031.vdocument.in/reader031/viewer/2022022120/5e86e59199ab3c76ec50f97f/html5/thumbnails/28.jpg)
Debra Brown, PharmD, Pharmaceutical Consultant II
California Department of Public Health
◦ Center for Healthcare Quality/Licensing and Certification Program
Email: [email protected]
Phone: (916) 319 - 9239
28